Skip to content

Study · Non-randomized trial · n = 14 · 2017

5 results

Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates.

Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research7 Feb 2017Cited by 43 (Europe PMC)

PMID28071822 (opens in a new tab)DOI10.1002/jbmr.3081 (opens in a new tab)PepBankPUB-28071822
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with atypical femur fractures after bisphosphonates, teriparatide increased lumbar spine BMD significantly at month 24.

    In plain wordsIn patients with atypical thigh fractures after bisphosphonates, teriparatide increased lower spine bone density compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD change
    6.1%
    month 24 versus baseline

    Source sentences

    Summary
    Lumbar spine BMD increased significantly at month 24 (6.1% ± 4.3%, p < 0.05 versus baseline), whereas total hip BMD and TBS did not change significantly.
    2 context sentences
    Summary · context
    We conducted a prospective, open-label study in patients previously treated with bisphosphonates who sustained AFF, examining the response to 24-month treatment with teriparatide on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers (BTM), and fracture healing as well as…
    Summary · context
    We studied 14 patients.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with atypical femur fractures after bisphosphonates, total hip BMD did not change significantly during teriparatide treatment.

    In plain wordsIn patients with atypical thigh fractures, hip bone density did not change significantly from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTotal hip BMD
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Lumbar spine BMD increased significantly at month 24 (6.1% ± 4.3%, p < 0.05 versus baseline), whereas total hip BMD and TBS did not change significantly.
    2 context sentences
    Summary · context
    We conducted a prospective, open-label study in patients previously treated with bisphosphonates who sustained AFF, examining the response to 24-month treatment with teriparatide on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers (BTM), and fracture healing as well as…
    Summary · context
    We studied 14 patients.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with atypical femur fractures after bisphosphonates, trabecular bone score did not change significantly during teriparatide treatment.

    In plain wordsIn patients with atypical thigh fractures, the bone structure score did not change significantly from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular bone score
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Lumbar spine BMD increased significantly at month 24 (6.1% ± 4.3%, p < 0.05 versus baseline), whereas total hip BMD and TBS did not change significantly.
    2 context sentences
    Summary · context
    We conducted a prospective, open-label study in patients previously treated with bisphosphonates who sustained AFF, examining the response to 24-month treatment with teriparatide on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers (BTM), and fracture healing as well as…
    Summary · context
    We studied 14 patients.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with atypical femur fractures previously treated with bisphosphonates, teriparatide increased bone turnover markers, as reported previously in patients without atypical femur fractures.

    In plain wordsIn patients with atypical thigh fractures, teriparatide treatment raised bone turnover markers, as seen in earlier reports.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone turnover markers
    Study

    n = 14

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with teriparatide resulted in increases in BTM and lumbar spine BMD, as has been reported for patients without AFF.
    Summary
    Changes in BTM occurred as reported previously for patients without AFF treated with teriparatide after prior bisphosphonate treatment.
  5. 05HumanNon-randomized trialEfficacy outcome

    At month 24 of teriparatide treatment, fractures healed in 6 patients, partly healed in 3, remained unchanged in 2, and showed nonunion in 1.

    In plain wordsDuring teriparatide treatment, fracture healing varied from complete healing to nonunion in patients with atypical thigh fractures.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedFracture healing at month 24
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Patients with healed fracture
    6 patients
    month 24
    Patients with partial healing
    3 patients
    month 24
    Patients with unchanged fracture
    2 patients
    month 24
    Patients with nonunion
    1 patients
    month 24

    Source sentences

    Summary
    At month 24, fractures were healed in 6 patients, showed partial healing in 3, were unchanged in 2, and showed nonunion in 1.
    2 context sentences
    Summary · context
    We conducted a prospective, open-label study in patients previously treated with bisphosphonates who sustained AFF, examining the response to 24-month treatment with teriparatide on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers (BTM), and fracture healing as well as…
    Summary · context
    We studied 14 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.